Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302938 · ClinicalTrials.gov registry record · Phase 4
Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Terminated
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT01302938 is a Phase 4 study that was terminated before completion, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 18 participants.
The verdict
NCT01302938, a Phase 4 study, was terminated before completion, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
To compare the effect of tolterodine ER 4 mg to placebo on patient reported outcomes in subjects with overactive bladder after 1, 4, and 12 weeks of treatment using an innovative web-based trial design
Interventions
- DRUG Placebo
- DRUG Tolterodine ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302938
The ClinicalTrials.gov registry entry for NCT01302938 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01302938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01302938 about?
NCT01302938 is a clinical study titled "Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder". To compare the effect of tolterodine ER 4 mg to placebo on patient reported outcomes in subjects with overactive bladder after 1, 4, and 12 weeks of treatment using an innovative web-based trial design
What is the current status of trial NCT01302938?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2011-03. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01302938?
The interventions under investigation include: Placebo (DRUG), Tolterodine ER (DRUG).
Who is sponsoring clinical trial NCT01302938?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.